# GRK4 Polymorphisms Blood Pressure Response to Candesartan

Study · id `cardio:ct-nct01629225` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01629225](<https://clinicaltrials.gov/study/NCT01629225>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01629225

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT01629225. Allocation not applicable; single masking; primary purpose treatment. Start 2013-07 (registry gives no type); primary completion 2015-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT01629225, source copy `cardio:ctgov-nct01629225-2014-11-18`, retrieved 2026-10-26)
- Start date: 2013-07 (registry gives no type) (ClinicalTrials.gov record NCT01629225, source copy `cardio:ctgov-nct01629225-2014-11-18`, retrieved 2026-10-26)
- Primary completion: 2015-07 (anticipated) (ClinicalTrials.gov record NCT01629225, source copy `cardio:ctgov-nct01629225-2014-11-18`, retrieved 2026-10-26)
- Completion: 2015-07 (anticipated) (ClinicalTrials.gov record NCT01629225, source copy `cardio:ctgov-nct01629225-2014-11-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01629225, source copy `cardio:ctgov-nct01629225-2014-11-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01629225-2014-11-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: GRK4 Polymorphisms Blood Pressure Response to Candesartan
- Condition: Essential Hypertension
- Intervention (Drug): Candesartan
- Lead sponsor: Third Military Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Candesartan (`cardio:candesartan`)
- Registry intervention is a member of this class by a sourced record link: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- Registry lists this organization as the lead sponsor: Third Military Medical University (`cardio:org-third-military-medical-university`)

## Provenance

Content hash: 2e6c4c8074675881ba65816f7801106c66de4360a303be78b6f7fd23737773fd
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
